Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 133.00p 131.00p 135.00p 133.00p 133.00p 133.00p 2,383.00 07:33:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -0.3 - 68.31

Verona Pharma Share Discussion Threads

Showing 12626 to 12650 of 12650 messages
Chat Pages: 506  505  504  503  502  501  500  499  498  497  496  495  Older
DateSubjectAuthorDiscuss
26/4/2017
00:34
http://www.nasdaq.com/markets/ipos/company/verona-pharma-plc-999545-83296
bewise2
19/4/2017
09:26
http://m.nasdaq.com/article/respiratory-biotech-verona-pharma-sets-terms-for-75-million-us-ipo-cm775580
bewise2
18/4/2017
10:27
Timbo, I couldn't go either. I was looking forward to your write up. The 3 year EIS lock-in is over but trading is thin. I guess the 150p (3p in old money)level is going to be a key indicator on sentiment
127tolmers
18/4/2017
10:05
Timbo,I attended the AGM, it was mentioned that the real money was in PDI &MDI and when Verona were in talks with the Chinese they wanted to see a hand held device. Which Verona are I the process of looking at. Could this have any bearing on things ?
aimshares
18/4/2017
09:46
Thanks for spotting that Kwizza I have fixed the main link to Verona's web site, although I see that there are also a few others (on the Verona web site) which now need updating, I have rectified a couple of them and will look at the rest when I have a bit more time later this week.
timbo003
18/4/2017
09:02
timbo, the link to Verona website above is not working, could you have a look
kwizza
18/4/2017
08:40
I couldn't make it to the AGM this year (I had it down in my diary for the day before), but I look forward to seeing the AGM slides on the web site. Today's announcement has me a bit puzzled With the IND effective, the Company plans to initiate a PK clinical trial in the middle of this year in approximately 12 healthy volunteers to determine the oral bioavailability of RPL554, as well as assess the safety and tolerability of the drug. Top-line data is expected in the fourth quarter of 2017. Are Verona considering developing an oral dosage form?
timbo003
07/4/2017
16:34
...not looking so good today?
haff1
04/4/2017
07:06
VRP true to their word (not usual for AIM). All the makings for the offer being oversubscribed too.
ewads
31/3/2017
14:57
Tim The strategy is clearer now in my view after today's announcement. Verona are clearly prepared to 'go it alone' - all the way if necessary and subject to funds. Thus the new collaborations to develop a DPI and MDI rather than any partnering with a big pharma who would no doubt want a deal on their own terms. In addition, bringing in Richard Hennings as the new Commercial Director seems to be linked with this strategy and brings more focus to Verona's own objectives. If all goes well then with current and future trials, I personally see Verona sticking to their own devices and formulations either as a stand alone company or one that is eventually bought out 'off the peg' so to speak and the offerings would then simply become part of a larger pharma's portfolio of offerings under the Verona 'brand'. All this of course does depend on the success of RPL554 in various trials. But I assume the new Commercial Director heard enough positives from our CEO to convince him to come on board at this stage. After all, this appointment is very different from the glut of NEDs appointed to the board who are mostly there on behalf of certain major investors.
vasilis
31/3/2017
09:23
>>>>Bonzo I assume they are both private companies (one for DPI and one for MDI) hence no need for them to be named or to announce themselves. I am a bit disappointed with today's news as the original plan (last year) was to partner mdi and dpi formats with a big pharma and big pharma to pay for the development, so this suggests to me that they still have no takers (at the right price). If they do end up getting a big pharma partner the work will have to be repeated using the partner's device and formulation.
timbo003
31/3/2017
09:06
Pity they do not say who the collaborations on DPI and MDI are with.
bonzo
22/3/2017
21:58
Todays RNS another step forward...
bewise2
21/3/2017
08:42
Annual report now published http://www.veronapharma.com/uploads/ctas/verona-pharma-plc-2016-annual-report-final-1488180437.pdf The AGM will be held on April 12th starting at 12:00, I plan to attend
timbo003
17/3/2017
08:38
Very interesting Tim and it looks like a change in strategy by AZ in disposing of the US rights of these aclidinium based treatments. As recently as November 2014 AZ made this statement in relation to Duaklir when they obtained EC marketing authorisation - 'The EU approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices.' See https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html# Why keep the EC rights yet give up the US rights? And Circassia propose to double their salesforce to promote Tudorza - so clearly they think that it's worth sinking money into promoting Tudorza whereas presumably AZ do not. I suspect that there's more to this than meets the eye as to the deal itself and the enhanced relationship between AZ and Circassia. Still, the deal once again raises the question as to what price the EU and US rights for a novel treatment such as RPL554 - which to date has not shown the side effects of aclidinium based medicines - might bring at some point in the future.
vasilis
17/3/2017
08:02
AN interesting announcement today from Circassia. I'm not sure what's in it for AZ. I guess they may think they have more than enough irons in the fire with their respiratory development portfolio http://www.investegate.co.uk/circassia-pharma-plc--cir-/rns/collaboration-with-astrazeneca/201703170700087819Z/
timbo003
28/2/2017
00:53
Timbo............and do you feel if it is marketed as a combo we would get any significant returns on share price bearing in mind the royalties also due to vernalis????????.Remember at old money 5p JAK said significant shareholder value. That in new money is £2.50 so would expect £5 to £7.50 and as a combo cannot see it. I would like your reasoning if you see the share price going to this. I do not and I personally am very disappointed but likelihood it is the best that we can expect under the current management and with the absence of any clinical leadership with Kathy now at GSK.
shakin not stirred
27/2/2017
15:05
Agreed Tim. I think Verona will also adopt the same approach if the current trial for RPL554 in CF patients goes well. Current inhaled steroid treatments as stated on the CF Trust website - 'The most commonly-used inhaled steroids are beclometasone (Becotide, Clenil, QVAR) and budesonide (Pulmicort), which both come as beige and brown inhalers, and fluticasone (Flixotide), which is an orange inhaler. Sometimes, steroids are combined in the same inhaler with a long-acting medicine that helps relax the muscles of the airways. These are Seretide (fluticasone plus salmeterol), which is a purple inhaler, or Symbicort (budesonide plus formoterol), which is a white turbohaler with a red base.' So I would also expect a Phase 2 combo trial for CF down the line all being well.
vasilis
27/2/2017
14:23
>>>>>the bossman, I doubt if there will ever be widespread use of RPL554 as a replacement for salbutamol or ipratropium, more likely it will be used in addition to Salbutamol and ipratropium and hopefully (eventually) it will be marketed as a combo. That would be good enough for me!
timbo003
27/2/2017
09:29
I'm amazed Piers ~Morgan has enough free time to take on an additional role given his busy schedule.
meijiman
27/2/2017
09:24
I like this bit of info stands out... When RPL554 was added to each of salbutamol or ipratropium bromide it caused a significant reduction (p=0.0002 and p=0.004 respectively) in trapped air in the lung (residual volume) as compared to salbutamol or ipratropium bromide alone, suggesting that RPL554 treatment may reduce dyspnea, a major debilitating symptom of COPD... So maybe 554 can be used instead of salbutamol or ipratropium a nice little earner me thinks... Also a few bob in the bank.. Net cash used in operating activities during the year of £5.59m (2015: £6.36m) reflecting clinical progress, with cash and cash equivalents as at 31 December, 2016 increasing to £39.79m (2015: £3.52m).
thebossman
27/2/2017
08:50
Excellent clinical summary in today's results of the NEW formulation - which is what has attracted the new institutional investors. We have both statistically significant results at Phase 2 when used as part of a combo plus excellent safety profile, wide dosage range, longevity of effects in the lungs and the 'gold standard' of twice daily dosing. RPL554 - in its new formulation - is clearly becoming a potentially very valuable clinical asset.
vasilis
27/2/2017
07:19
From this mornings RNS it looks like we are onto a winner..
thebossman
23/2/2017
11:23
Unless you bought in at a penny in which case showing a profit.
shakin not stirred
23/2/2017
11:22
I am waiting to see if Nasdaq listing makes a difference but need to get to £2 new money to break even. Will bale out when that is reached. Unless anything materially changes as to indicating a good news flow. At the moment it is a Jam tomorrow as have been the last few years for me and longer for others. None of us have invested in companys for F.A. but that is the current return at this moment in time. That is the current reality of the share price.
shakin not stirred
Chat Pages: 506  505  504  503  502  501  500  499  498  497  496  495  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170426 15:53:51